Weibo (WB) Overweight Rating Reaffirmed by JP Morgan; With $140 Target; Redmile Group Has Raised Its Seattle Genetics (SGEN) Position

February 15, 2018 - By Vivian Currie

Among 12 analysts covering Weibo Corp (NASDAQ:WB), 9 have Buy rating, 0 Sell and 3 Hold. Therefore 75% are positive. Weibo Corp has $150.0 highest and $14 lowest target. $77.22’s average target is -43.32% below currents $136.24 stock price. Weibo Corp had 22 analyst reports since August 19, 2015 according to SRatingsIntel. As per Friday, August 5, the company rating was initiated by Citigroup. The company was maintained on Wednesday, February 14 by Barclays Capital. The rating was maintained by Jefferies on Thursday, June 22 with “Buy”. The stock of Weibo Corporation (NASDAQ:WB) earned “Overweight” rating by Barclays Capital on Wednesday, November 15. The firm has “Overweight” rating given on Friday, August 11 by Barclays Capital. Jefferies maintained Weibo Corporation (NASDAQ:WB) rating on Tuesday, January 23. Jefferies has “Buy” rating and $150.0 target. On Tuesday, November 17 the stock rating was maintained by TH Capital with “Buy”. The firm has “Hold” rating by Zacks given on Friday, September 4. On Tuesday, October 3 the stock rating was maintained by Jefferies with “Buy”. On Thursday, August 11 the stock rating was maintained by Goldman Sachs with “Neutral”.

Redmile Group Llc increased Seattle Genetics Inc (SGEN) stake by 177.2% reported in 2017Q3 SEC filing. Redmile Group Llc acquired 1.18 million shares as Seattle Genetics Inc (SGEN)’s stock rose 1.68%. The Redmile Group Llc holds 1.84M shares with $100.32 million value, up from 665,139 last quarter. Seattle Genetics Inc now has $8.46B valuation. The stock increased 0.76% or $0.41 during the last trading session, reaching $54.47. About 93,612 shares traded. Seattle Genetics, Inc. (NASDAQ:SGEN) has risen 75.68% since February 15, 2017 and is uptrending. It has outperformed by 58.98% the S&P500.

Redmile Group Llc decreased Jounce Therapeutics Inc stake by 182,772 shares to 955,598 valued at $14.89M in 2017Q3. It also reduced Cascadian Therapeutics Inc stake by 1.77 million shares and now owns 1.97M shares. Audentes Therapeutics Inc was reduced too.

Since August 24, 2017, it had 1 buy, and 16 insider sales for $189.84 million activity. Shares for $305,423 were sold by HIMES VAUGHN B on Monday, August 28. Shares for $260,967 were sold by Cline Darren S on Wednesday, September 6. $501,176 worth of Seattle Genetics, Inc. (NASDAQ:SGEN) was sold by SIMPSON TODD E. SIEGALL CLAY B also sold $1.22M worth of Seattle Genetics, Inc. (NASDAQ:SGEN) on Monday, August 28. 8,502 shares valued at $407,199 were sold by DRACHMAN JONATHAN G on Monday, August 28. Another trade for 3.85M shares valued at $200.00 million was bought by BAKER BROS. ADVISORS LP. $255,900 worth of Seattle Genetics, Inc. (NASDAQ:SGEN) was sold by DOBMEIER ERIC on Monday, August 28.

Among 18 analysts covering Seattle Genetics (NASDAQ:SGEN), 9 have Buy rating, 0 Sell and 9 Hold. Therefore 50% are positive. Seattle Genetics had 64 analyst reports since July 31, 2015 according to SRatingsIntel. William Blair maintained the shares of SGEN in report on Tuesday, August 25 with “Buy” rating. The stock of Seattle Genetics, Inc. (NASDAQ:SGEN) earned “Buy” rating by RBC Capital Markets on Friday, October 27. The firm has “Equal-Weight” rating given on Tuesday, November 29 by Barclays Capital. The stock of Seattle Genetics, Inc. (NASDAQ:SGEN) has “Buy” rating given on Wednesday, February 14 by J.P. Morgan. The firm has “Overweight” rating by Barclays Capital given on Wednesday, July 27. The company was maintained on Monday, October 10 by RBC Capital Markets. The firm has “Hold” rating by Oppenheimer given on Friday, June 2. The rating was maintained by H.C. Wainwright with “Buy” on Friday, October 27. SunTrust maintained it with “Hold” rating and $52.0 target in Friday, October 27 report. The rating was maintained by H.C. Wainwright on Thursday, February 1 with “Buy”.

Investors sentiment decreased to 0.78 in 2017 Q3. Its down 0.52, from 1.3 in 2017Q2. It is negative, as 51 investors sold SGEN shares while 74 reduced holdings. 29 funds opened positions while 69 raised stakes. 140.23 million shares or 2.00% more from 137.48 million shares in 2017Q2 were reported. Pioneer Tru Bancorp N A Or holds 0.28% of its portfolio in Seattle Genetics, Inc. (NASDAQ:SGEN) for 10,000 shares. Toronto Dominion Retail Bank has invested 0% in Seattle Genetics, Inc. (NASDAQ:SGEN). Shine Investment Advisory owns 157 shares. Campbell And Adviser Ltd reported 5,356 shares or 0.24% of all its holdings. Ahl Ptnrs Llp holds 0.01% or 6,015 shares. Ascend Capital Ltd reported 164,648 shares. Archon Prtn Lc reported 0.08% stake. New York-based Mufg Americas Hldg has invested 0% in Seattle Genetics, Inc. (NASDAQ:SGEN). Strs Ohio stated it has 0% in Seattle Genetics, Inc. (NASDAQ:SGEN). Swiss National Bank & Trust has invested 0.02% in Seattle Genetics, Inc. (NASDAQ:SGEN). Raymond James And Assocs invested in 6,950 shares or 0% of the stock. Fairfield Bush And holds 0.29% or 16,772 shares. Livforsakringsbolaget Skandia Omsesidigt accumulated 0.01% or 1,900 shares. Whittier Trust Of Nevada Incorporated holds 189 shares or 0% of its portfolio. Massachusetts-based Tekla Mngmt Limited Liability Co has invested 0.44% in Seattle Genetics, Inc. (NASDAQ:SGEN).

Weibo Corporation operates as a social media platform for people to create, distribute, and discover Chinese-language content. The company has market cap of $30.14 billion. It operates through two divisions, Advertising and Marketing Services, and Other Services. It has a 87.33 P/E ratio. The firm offers self-expression products that enable its users to express themselves on its platform; social products to promote social interaction between users on its platform; discovery products to help users discover content on its platform; and notifications to notify users on Weibo account activities through SMS or push notification on their device.

Analysts await Weibo Corporation (NASDAQ:WB) to report earnings on February, 28. They expect $0.52 EPS, up 173.68% or $0.33 from last year’s $0.19 per share. WB’s profit will be $115.03M for 65.50 P/E if the $0.52 EPS becomes a reality. After $0.45 actual EPS reported by Weibo Corporation for the previous quarter, Wall Street now forecasts 15.56% EPS growth.

The stock decreased 2.43% or $3.4 during the last trading session, reaching $136.24. About 1.17 million shares traded. Weibo Corporation (NASDAQ:WB) has risen 239.00% since February 15, 2017 and is uptrending. It has outperformed by 222.30% the S&P500.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: